According to the business research report titled ‘Connected Drug Delivery Devices Market Size By Device Type [Connected Sensors {Connected Inhalation Sensors, Connected Injectable Sensors}, Integrated Devices {Integrated Inhalation Devices, Integrated Injectable Devices,}], By Technology [Bluetooth, Near Field Communication, Wi-Fi], By Application [Anaphylaxis, Respiratory, Cardiovascular, Diabetes, Hormone Replacement], By End-use [Hospital, Clinics, Homecare], COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027’, available with MarketStudyReport, the connected drug delivery devices market is slated to grow substantially throughout the forecast period 2021-2027.
 

Industry experts cite that an increase in the occurrences of chronic diseases, improving healthcare IT infrastructure, awareness among patients, and surge in the adoption of machine learning and artificial intelligence are fueling connected drug delivery devices market growth.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4202297/

Further, rising inclination towards home-based care among patients who require prolonged therapy, as well as the improved efficiency of connected drug delivery devices have aided in the augmentation of the industry in recent years.

However, the expenditure incurred for the product and security concerns with respect to patient data may impede market demand during the assessment timeframe.

Moving on to segmentation, worldwide connected drug delivery devices marketplace has been fragmented on the basis of technology, device type, end use, application, and region.

Based on device type, the market is further divided into integrated devices and connected sensors. The connected sensors sub-segment amassed a valuation exceeding USD 117.5 Mn in 2020 and is expected to witness an appreciable growth rate during the stipulated time period.

From the perspective of application, the anaphylaxis sub-segment is the most promising in terms of growth rate and anticipated to surpass USD 224.9 Mn by 2027.

Speaking of the end user scope, the sub -segment of clinics is anticipated to record a hefty growth rate of around 35.3 % during 2021-2027.

From a regional frame of reference, Middle East and Africa connected drug delivery devices market is projected to showcase a CAGR of more than 35.9% during the evaluation period. Meanwhile, the Latin America market is anticipated to progress at a CAGR of 9.9 through 2027.

The competitive landscape of this business sphere is defined by key players like West Pharmaceutical Services, Inc., Bayer AG, Nemera La Verpilliere, Phillips-Medsize Corporation, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Propeller Health, FindAir Sp z.o.o, Biocorp Production, and Adherium Ltd.